Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6010156 | 0.80 | OR51E2 (0.34) | — | |
| SCHEMBL6009483 | 0.80 | TET2 (0.38) | FOLH1 | |
| SCHEMBL6009578 | 0.78 | MME (0.36) | RNPEP | |
| SCHEMBL6009562 | 0.76 | RNPEP (0.42) | RNPEPFOLH1 | |
| SCHEMBL6009570 | 0.76 | RNPEP (0.42) | RNPEPFOLH1 | |
| SCHEMBL6010353 | 0.72 | KDM4E (0.35) | — | |
| SCHEMBL6009867 | 0.72 | CYP1A2 (0.42) | — | |
| SCHEMBL6010239 | 0.71 | SLC1A1 (0.31) | — | |
| SCHEMBL6009555 | 0.70 | RNPEP (0.42) | RNPEPFOLH1 | |
| SCHEMBL6010244 | 0.70 | MAPK1 (0.41) | RNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | SEIWA KASEI COMPANY, LIMITED (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1584320-A1 | COSMETIC PREPARATION CONTAINING GLYCERYLAMINO ACID DERIVATIVE | Seiwa Kasei Company, Limited (JP) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | GLA, GPKOW, CUTA | RNPEP 2950/4885FOLH1 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.